NEW YORK (GenomeWeb) – Alere reported on Thursday a 3 percent drop year over year in its first quarter revenues as it restated its first quarter earnings. 

In its Form 10-Q filed with the US Securities and Exchange Commission, the company said that for the three months ended March 31 total revenues came in at $608.2 million, compared to $625.2 million in the year-ago quarter. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.